Macquarie Group LTD Palatin Technologies Inc Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$0.67 - $1.01 $20,788 - $31,337	-31,027 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$0.63 - $1.0 $31,506 - $50,011	-50,011 Reduced 61.71%	31,027 $22,000
Q3 2018 Nov 15, 2018	SELL	$0.88 - $1.1 $285,886 - $357,358	-324,871 Reduced 80.04%	81,038 $81,000
Q2 2018 Aug 14, 2018	SELL	$0.91 - $1.45 $583,307 - $929,445	-640,997 Reduced 61.23%	405,909 $394,000
Q1 2018 May 11, 2018	BUY	$0.84 - $1.18 $481,824 - $676,848	573,600 Added 121.19%	1,046,906 $1.14 Million
Q4 2017 Feb 15, 2018	BUY	$0.68 - $1.0 $272,510 - $400,750	400,750 Added 552.33%	473,306 $407,000
Q3 2017 Nov 08, 2017	BUY	$0.39 - $0.66 $28,296 - $47,886	72,556	72,556 $48,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $10.3M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.